Document Detail

A prospective study of methylprednisolone and prednisone as immunosuppressive agents in clinical renal transplantation.
MedLine Citation:
PMID:  7022849     Owner:  NLM     Status:  MEDLINE    
A prospective double blind crossover study was carried out in 65 patients comparing methylprednisolone (Medrol) and prednisone as immunosuppressive agents in clinical renal transplantation to determine their relative merits vis-a-vis graft survival, hypertension, weight gain, sepsis and patient preference in the posttransplant period. Patients receiving renal allografts were randomly assigned to receive initial treatment with one of the drugs. Once maintenance doses were employed, the drug was switched for a 3-month period. There was no difference in overall graft survival at 1 year, 68% versus 56% (p greater than 0.4), for the two patient groups. Likewise, there was no difference in blood pressure during the maintenance therapy crossover period, mean BP 129/86 during Medrol therapy and 129/86 during prednisone therapy. Overall weight gain was not statistically different with the two drugs, 3.8 kg with prednisone and 2.3 kg with Medrol, p greater than 0.1. However, when Medrol was used in the late posttransplant period, the patient had a significantly smaller weight gain, 0.95 kg versus 3.5 kg with prednisone, p greater than 0.05. The incidence of bacterial sepsis was significantly greater (p less than 0.02) during the early posttransplant period in those patients treated with Medrol. Finally, the majority of patients (65%) had no preference for either drug. Of those with a preference, the majority (69%) preferred Medrol. We conclude that therapy with Medrol does not offer superior graft survival, less hypertension or overriding patient preference but does apparently lead to an increased incidence of bacterial sepsis in the early posttransplant period. Thus it appears that prednisone is the initial drug of choice as an immunosuppressive steroid in clinical renal transplantation.
R L Burleson; P D Marbarger; N Jermanovich; A M Brennan; B F Scruggs
Related Documents :
7491699 - Microangiopathy following allogeneic marrow transplantation. association with cyclospor...
22057239 - Low densities of serotonin and peptide yy cells in the colon of patients with irritable...
14575279 - A longitudinal study of the yield and clinical utility of a specifically designed secon...
2176809 - Typology of na+ transport abnormalities in erythrocytes from essential hypertensive pat...
3966509 - The significance of a previous stillbirth.
569669 - Idiopathic hypertrophic subaortic stenosis as observed in a large community hospital: r...
21870999 - Parkinson-like features in als with predominant upper motor neuron involvement.
3469849 - The quality and diagnostic outcome of postbronchoscopic sputum.
23376659 - Dropped head with positive intravenous edrophonium, progressing to myasthenia gravis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation proceedings     Volume:  13     ISSN:  0041-1345     ISO Abbreviation:  Transplant. Proc.     Publication Date:  1981 Mar 
Date Detail:
Created Date:  1981-10-14     Completed Date:  1981-10-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  339-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Double-Blind Method
Graft Survival / drug effects
Immunosuppressive Agents*
Kidney Transplantation*
Methylprednisolone / pharmacology*
Prednisone / pharmacology*
Prospective Studies
Random Allocation
Transplantation Immunology
Reg. No./Substance:
0/Immunosuppressive Agents; 53-03-2/Prednisone; 83-43-2/Methylprednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Posttransplant serum analysis in human kidney allografts.
Next Document:  Sixteen months experience with cyclosporin-A in human kidney transplantation.